Issues of spectrum and local sensitivity of E. coli in female patients with acute uncomplicated lower urinary tract infection - a review of M. Seitz study and own observations


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Relevance. Acute uncomplicated lower urinary tract infections (AULUTI) are one of the most common diseases in urological practice. The management of cystitis is commonly based on antibacterial therapy. Despite the high efficiency, inadequate prescription of antibiotics leads to an increase in microorganisms’ resistance. In light of these matters, the selection of antibacterial agents to which the sensitivity of bacteria is the highest is becoming increasingly challenging. Aim. To estimate the spectrum and local sensitivity of E. coli in patients with AULUTI. Materials and methods. The present study analyzed the results of bacterial culture sampled from 45 patients with AULUTI. The mean age of the patients was 44±17 years. All bacterial cultures were obtained in out patient settings in the framework of a multicenter initiative study on the prevention of recurrent AULUTI with d-mannose. Results. Microbiological studies of the urine of patients with AULUTI revealed the growth of E. coli in concentrations ranging from 104 to 107 CFU/ml. Assessment of sensitivity demonstrated 100% sensitivity of Escherichia coli to fosfomycin trometamol. Conclusion. According to the findings of microbiological studies, the patients with the AULUTI retain the highest sensitivity level of E.coli to phosphomycin trometamol, which allows it to be used as a first-line drug.

Full Text

Restricted Access

About the authors

L. G Spivak

I.M. Sechenov First MSMU of Minzdrav of Russia (Sechenov University)

Email: leonid.spivak@gmail.com
Associate Professor at the Department of Urology

L. M Rapoport

I.M. Sechenov First MSMU of Minzdrav of Russia (Sechenov University); Research Institute of Uronephrology and Human Reproductive Health

Email: leonidrapoport@yandex.ru
Dr.Med.Sci., Prof. at the Department of Urology, Deputy Director for Medical work

D. V Platonova

I.M. Sechenov First MSMU of Minzdrav of Russia (Sechenov University)

Junior Researcher at the Research Institute for Uronephrology and Human Reproductive Health

D. G Tsarichenko

I.M. Sechenov First MSMU of Minzdrav of Russia (Sechenov University)

Email: tsarichenkodg@yandex.ru
Dr.Med.Sci., Professor at the Department of Urology

M. S Evdokimov

LLC «Family Polyclinic 4»

Ph.D., Urologist of the Highest Category, General Director, Chief Physician

Yu. L Demidko

I.M. Sechenov First MSMU of Minzdrav of Russia (Sechenov University)

Dr.Med.Sci., Urologist at the UCH #2

D. V Enikeev

I.M. Sechenov First MSMU of Minzdrav of Russia (Sechenov University)

Ph.D., Deputy Director for Clinical Care of the Research Institute for Uronephrology and Human Reproductive Health

A. N Rossolovsky

Saratov state medical University. V. I. Razumovsky Ministry of health of Russia

Email: rossol@list.ru
MD, associate Professor, associate Professor of urology

References

  1. Seitz et al. Local epidemiology and resistance profiles in acute uncomplicated cystitis (AUC) in women: a prospective cohort study in an urban urological ambulatory setting. BMC Infectious Diseases. 2017;17:685.
  2. Винаров А.З. Современные подходы к диагностики и лечению неосложненной инфекции мочевыводящих путей: результаты исследования ARESC. Эффективная фармакотерапия. 2009;13:12-17
  3. Resolution of the expert council on topical issues of therapy for patients with lower urinary tract infections. Effektivnaya farmakoterapiya. 2016;11:8-11.
  4. Резолюция экспертного совета, посвященного актуальным вопросам терапии пациентов с инфекцией нижних мочевых путей. Эффективная фармакотерапия. 2016;11:8-11
  5. Wagenlehner F.N. et al. Uncomplicated urinary tract infections. Dtsch ArzteblInt.2011.108:415.https://www.ncbi.nlm.nih.gov/pubmed/21776311
  6. Lecomte F., Allaert F.A. Single-dose treatment of cystitis with fosfomycin trometamol (Monuril): analysis of 15 comparative trials on 2,048 patients. Giorn It Ost Gin. 1997;19:399-404.
  7. Nicolle L.E. Pivmecillinam in the treatment of urinary tract infections. J. Antimicrob Chemother. 2000;46 (Suppl. 1):35-39; discussion 63-65.
  8. Kahlmeter G., Eco Sens. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS project. J. Antimicrob Chemother. 2003;51(1):69-76.
  9. Naber K. et al. Eur Urol. 2008;54:1164-1117.
  10. Палагин И.С., Сухорукова М.В. и др., исследовательская группа «ДАРМИС» Современное состояние антибиотикорезистентности возбудителей внебольничных инфекций мочевых путей в России: результаты исследования «ДАРМИС» (2010-2011). Клиническая микробиология и антимикробная химиотерапия. 2012;14(4):280-302
  11. Kahlmeter G., Poulsen H.O. Antimicrobial susceptibility of Escherichia Coli from community-acquired urinary tract infections in Europe: the ECO. SENS study revisited. Int J. Antimicrob Agents. 2012;39(1):45-51.
  12. Kahlmeter G., Ahman J., Matuschek E. Antimicrobial resistance of escherichia coli causing uncomplicated urinary tract infections: a European update for 2014 and comparison with 2000 and 2008. Infect Dis Ther. 2015;4(4):417-423.
  13. Bonkat G. et al. Urological Infections. European Association of Urology Guidelines, 201. Р. 14.
  14. Яровой С.К. Место Фосфомицина в терапии заболеваний мочевой системы. Экспериментальная и клиническая урология. 2013;4:115-120
  15. Синякова Л.А. Антибактериальная терапия острого цистита в Эру растущей резистентности возбудителей. Терапевтический архив. 2014;86(4):125-129

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Bionika Media